 |
Robert L. Kirkman, MD
President and CEO
ROBERT L. KIRKMAN, M.D. has served as our president and chief executive officer since September 2006. From 2005 to 2006, Dr. Kirkman was acting president and chief executive officer of Xcyte Therapies, which concluded a merger with Cyclacel Pharmaceuticals, both development-stage biopharmaceuticals companies, in March of 2006. From 2004 to 2005, Dr. Kirkman was chief business officer and vice president of Xcyte. From 1998 to 2003, Dr. Kirkman was vice president, business development and corporate communications of Protein Design Labs, a biopharmaceuticals company. Dr. Kirkman holds an M.D. degree from Harvard Medical School and a B.A. in economics from Yale University.
return to top ^
Gary Christianson, PE
Chief Operating Officer
GARY CHRISTIANSON was appointed as our chief operating officer in July 2007. From 2005 to 2007, Mr. Christianson was site director for the Biologics Unit of GlaxoSmithKline plc, a global healthcare company. From 1999 to 2003, Mr. Christianson was vice president, technical operations at Corixa Corp., a biopharmaceutical and biotechnology company, and from 2003 to 2005, he was general manager of the Hamilton, Montana site in addition to his duties as vice president. From 1987 to 1999, Mr. Christianson held various positions at RIBI ImmunoChem Research, a biopharmaceuticals company. Mr. Christianson received a B.S. in mechanical engineering technology from Montana State University and is a licensed and board certified professional engineer.
return to top ^
Diana Hausman, MD
Vice President, Clinical Development
DIANA HAUSMAN, MD was appointed as Vice President, Clinical Development in September, 2009. Prior to joining Oncothyreon, Dr. Hausman held a number of clinical research positions at ZymoGenetics, Inc. from 2005 to 2009, most recently as Senior Director of Clinical Research with responsibility for all therapeutic areas, including oncology, autoimmune disease and virology. Prior to Zymogenetics, Dr. Hausman led a global drug development team at Berlex Inc. in Seattle from 2002 until 2005. Dr. Hausman received her training in medical oncology from the University of Washington, and holds an M.D. degree from the University of Pennsylvania and an A.B. in Biology from Princeton University.
return to top ^
Scott Peterson, PhD
Vice President, Research and Development
SCOTT R. PETERSON, PHD joined Oncothyreon in August of 2009. From 2007-2009, Dr. Peterson was Director of Oncology Research at ZymoGenetics. Prior to that, Dr. Peterson was a Principal Scientist at ICOS Corporation where he led both small molecule and antibody cancer drug discovery programs. Dr. Peterson has a Ph. D. in Chemistry from the University of Colorado, Boulder and a B.S. in Biology from Washington State University.
return to top ^
Shashi Karan
Corporate Controller
SHASHI KARAN has served as our Corporate Controller since April 2008. Mr. Karan was appointed as our principal financial officer and principal accounting officer, effective January 1, 2009. From 2006 to 2007, Mr. Karan acted as a consultant, providing financial and accounting advice to various clients, with a focus on publicly-traded companies. From 2001 to 2005, Mr. Karan was vice president of finance of MusicNet Inc., a private online media company. From 1992 to 2000, Mr. Karan was senior director and corporate controller of Pathogenesis Corporation, a publicly-traded biotechnology company. Mr. Karan has been certified as a CPA in the State of Washington and received a B.A. (with honors) in economics from Leeds University, United Kingdom, and an M.S. in accounting from Long Island University and an M.S. in tax from Golden Gate University.
return to top ^
|
|
